Anxiety disorders are among the most common mental health conditions worldwide and are often accompanied by gastrointestinal symptoms. The gut-brain axis has emerged as a key pathway linking psychological and gastrointestinal disorders. Irritable bowel syndrome (IBS), affecting about 14% of the global population, is a functional gastrointestinal disorder associated with impaired quality of life and health care utilization. While most studies have examined anxiety prevalence in IBS, the reverse association remains underexplored. Addressing this gap is crucial, as gastrointestinal symptoms in anxious patients may be underrecognized or misattributed. This systematic review and meta-analysis aims to estimate the prevalence of IBS in adults with anxiety disorders. PubMed, Embase, and Cochrane are being searched for observational studies in adults published up to 2025. Inclusion criteria include validated anxiety diagnoses and IBS defined by Rome criteria or clinical evaluation. Data extraction and risk-of-bias assessment follow PRISMA guidelines. Preliminary evidence suggests a higher prevalence of IBS in anxious patients than in the general population. Analyses are ongoing. The final results will be presented at the meeting. This study will provide quantitative evidence on the prevalence of IBS in anxiety disorders, complementing prior meta-analyses focused on psychological comorbidities in IBS, by including studies published through 2024 and 2025.